Skeletal-Muscle Metabolic Reprogramming in ALS-SOD1G93A Mice Predates Disease Onset and Is A Promising Therapeutic Target - Archive ouverte HAL Access content directly
Journal Articles iScience Year : 2020

Skeletal-Muscle Metabolic Reprogramming in ALS-SOD1G93A Mice Predates Disease Onset and Is A Promising Therapeutic Target

(1, 2) , (1) , (1) , (3) , (3) , (2) , (3) , (1) , (1) , (2, 4) , (5) , (5) , (5) , (6) , (6) , (7) , (1, 8) , (1) , (1, 4) , (1, 4)
1
2
3
4
5
6
7
8

Abstract

Patients with ALS show, in addition to the loss of motor neurons in the spinal cord, brainstem, and cerebral cortex, an abnormal depletion of energy stores alongside hypermetabolism. In this study, we show that bioenergetic defects and muscle remodeling occur in skeletal muscle of the SOD1G93A mouse model of ALS mice prior to disease onset and before the activation of muscle denervation markers, respectively. These changes in muscle physiology were followed by an increase in energy expenditure unrelated to physical activity. Finally, chronic treatment of SOD1G93A mice with Ranolazine, an FDA-approved inhibitor of fatty acid β-oxidation, led to a decrease in energy expenditure in symptomatic SOD1G93A mice, and this occurred in parallel with a robust, albeit temporary, recovery of the pathological phenotype.
Fichier principal
Vignette du fichier
1-s2.0-S2589004220302728-main.pdf (5.8 Mo) Télécharger le fichier
Origin : Publication funded by an institution

Dates and versions

inserm-03376305 , version 1 (13-10-2021)

Identifiers

Cite

Silvia Scaricamazza, Illari Salvatori, Giacomo Giacovazzo, Jean Philippe Loeffler, Frederique Renè, et al.. Skeletal-Muscle Metabolic Reprogramming in ALS-SOD1G93A Mice Predates Disease Onset and Is A Promising Therapeutic Target. iScience, 2020, 23 (5), pp.101087. ⟨10.1016/j.isci.2020.101087⟩. ⟨inserm-03376305⟩

Collections

INSERM SITE-ALSACE
11 View
27 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More